Skip to main content
. 2018 Apr 3;11:1767–1776. doi: 10.2147/OTT.S154853

Figure 1.

Figure 1

Metformin inhibits CD19-CAR T-cell proliferation. (A) Schematic of construct of CD19-targeted CAR. (B) Transfection efficiency of CD19-CAR T cells. The expression of CD19-targeted CAR was detected by flow cytometry. (C) CD19-CAR T cells were treated with metformin (0, 1, 10, and 20 mM) for 24 hours. The proliferation of CD19-CAR T cells was detected by the CCK-8 assay. (D) Growth curves of CD19-CAR T cells. CD19-CAR T cells treated with metformin (0, 1, 10, and 20 mM) were counted by using a hemocytometer over 12 days of incubation *P<0.05, **P<0.01 versus the control group. The results are represent as mean ± SD from three independent experiments.

Abbreviations: CAR, chimeric antigen receptor; Met, metformin; LTR, long terminal repeat; CTS, Cis-acting termination zone; RRE, rev-response element; VH, variable region of heavy chain; VL, variable region of light chain; TM, transmembrane; OD, optical density.